Texas Permanent School Fund Corp Reduces Stock Position in Kenvue Inc. $KVUE

Texas Permanent School Fund Corp cut its stake in Kenvue Inc. (NYSE:KVUE) by 34.8% in the second quarter, HoldingsChannel.com reports. The fund owned 134,967 shares of the company’s stock after selling 72,056 shares during the period. Texas Permanent School Fund Corp’s holdings in Kenvue were worth $2,825,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Vanguard Group Inc. grew its position in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after purchasing an additional 4,101,880 shares during the period. Geode Capital Management LLC boosted its stake in shares of Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after buying an additional 604,953 shares during the last quarter. Independent Franchise Partners LLP boosted its stake in shares of Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after buying an additional 21,886,537 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Kenvue by 38.6% in the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after acquiring an additional 8,436,166 shares during the period. Finally, Norges Bank purchased a new stake in Kenvue during the second quarter valued at $537,418,000. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Kenvue

In other Kenvue news, Director Jeffrey C. Smith acquired 3,200,000 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.68% of the stock is currently owned by company insiders.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $17.02 on Friday. The company has a market capitalization of $32.61 billion, a P/E ratio of 22.69 and a beta of 0.60. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The firm’s 50 day simple moving average is $16.29 and its two-hundred day simple moving average is $18.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same period in the prior year, the company posted $0.28 earnings per share. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. The ex-dividend date was Wednesday, November 12th. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Jefferies Financial Group dropped their target price on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a report on Friday, September 26th. UBS Group cut their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and cut their price objective for the company from $22.50 to $22.00 in a research report on Friday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $20.23.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.